Latest Us Expansion News

HeraMED reports strong Q1 FY25 progress with 4,282 registered users on its HeraCARE platform, a new collaboration with Garmin Health, and advancing commercial deals in the US and Europe. Early clinical data suggests improved maternal outcomes and operational efficiencies.

Ovanti Limited has taken decisive steps to accelerate its US Buy Now Pay Later (BNPL) market entry, appointing an interim CEO and securing a pivotal 20-year licensing agreement with BNPLPay Protocol that offers low-cost funding and a significant revenue share.

Clime Investment Management has been appointed lead manager for a significant US public offer fund by Sphinx Investments, with initial allocations of $183 million AUD pending SEC approval. The move marks a strategic expansion into the US market, complemented by new wholesale offerings and a partnership with a Dallas-based equities manager.

FBR Limited wraps up its US Demonstration Program, secures $6.3 million in capital, and appoints Mark Pivac as CEO amid a 70% cost reduction drive. Strategic collaborations with Samsung Heavy Industries and Liebherr signal broader automation ambitions.

Inventis Limited reported solid Q3 cash generation and strong technology sales growth, while actively pursuing international expansion and a $2.5 million USD capital raise for its US Hazavoid entity.

Genetic Signatures Ltd reported a robust 71% jump in quarterly sales to $2.9 million, fueled by strong respiratory testing demand in Australia and key US commercial contracts. The company is advancing its automation and instrument customisation strategy to streamline molecular diagnostics offerings.

Global Uranium and Enrichment Limited has completed a transformative acquisition of the Pine Ridge Uranium Project in Wyoming, backed by a A$10 million capital raise and strategic partnership with Snow Lake Energy. This positions the company for near-term uranium production in the US’s premier ISR basin while advancing multiple other uranium assets.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.

Australian Strategic Materials (ASM) has made significant strides in its mine to metals strategy during the March 2025 quarter, including plans for US expansion and progress at its Dubbo Project and Korean Metals Plant. The company is positioning itself as a key alternative supply chain amid escalating geopolitical tensions and export restrictions.

Identitii Limited advances its BNDRY platform with new agreements targeting hospitality and payments sectors, appoints Tim Phillipps as Executive Chair, and reports stable cash flow amid ongoing patent litigation.

Echo IQ Limited marked a pivotal quarter with FDA clearance for EchoSolv AS, strategic US partnerships, and a clear path toward reimbursement and broader commercialisation.

Vitrafy Life Sciences reported strong Q3 FY2025 progress, including a successful US Army blood platelet study, a $4.8 million government grant, and strategic US market expansion.